Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has an ongoing Phase 2/3 clinical program for patients with notalgia paresthetica (NP), a neuropathic disorder characterized by chronic pruritus of the upper back for which there are no FDA-approved therapies.
